中华肝胆外科杂志
中華肝膽外科雜誌
중화간담외과잡지
Chinese Journal of Hepatobiliary Surgery
2015年
10期
658-663
,共6页
陈焕伟%邓斐文%吴志鹏%刘洪珍%欧伟明%誉铁鸥%方滨%李庆生%梁丽姬
陳煥偉%鄧斐文%吳誌鵬%劉洪珍%歐偉明%譽鐵鷗%方濱%李慶生%樑麗姬
진환위%산비문%오지붕%류홍진%구위명%예철구%방빈%리경생%량려희
脑死亡供体%脑心双死亡供体%肝移植%预后
腦死亡供體%腦心雙死亡供體%肝移植%預後
뇌사망공체%뇌심쌍사망공체%간이식%예후
Brain death donor%Brain and cardiac death donor%Liver transplantation%Prognosis
目的 探讨脑心死亡供体(DBCD)肝移植的可行性和安全性.方法 2011年9月至2014年4月,佛山市第一人民医院采用Maastricht标准或中国标准,共获取39例脑心死亡供肝.其中我院自行肝移植32例,5例供肝通过中国人体器官分配与共享系统(COTRS系统)分配到外院,2例弃用;对39例供体及佛山市第一人民医院完成的33例肝移植(1例供肝通过COTRS系统分配获得)的临床资料进行回顾性分析总结.结果 33例供体中,中国Ⅰ类(C-Ⅰ),脑死亡供体(DBD)11例,中国Ⅲ类(C-Ⅲ),DBCD 22例.供者中位年龄38岁,脑死亡原因:车祸伤22例,脑出血10例,脑干肿瘤1例.DBCD供肝的热缺血时间为3~21 min,平均为9.5 min;DBCD和DBD冷缺血时间为3.8~12.5 h,平均为5.2h.33例受者年龄38 ~64岁,中位年龄47.5岁.原发病包括原发性肝细胞癌11例,乙型肝炎后肝硬化8例,乙型肝炎急性肝功能衰竭6例,乙型肝炎慢加急性肝功能衰竭3例,丙型肝炎急性肝衰竭、乙肝合并丙肝肝硬化、自身免疫性肝炎、酒精性肝硬化、多囊肝合并多囊肾各1例.中位等待时间30 d,术后平均住院时间28.0 d,中位随访时间54周(13.5个月).术后32例受者存活,无原发性肝无功能发生,1例术后第9天死于多器官功能衰竭.结论 脑心死亡供体肝移植是安全和可行的.供体的评估和有效维护,缩短热、冷缺血时间,胆道并发症的防治,无激素免疫抑制方案以及核苷类似物的应用等是保证供体肝移植成功实施的关键因素.
目的 探討腦心死亡供體(DBCD)肝移植的可行性和安全性.方法 2011年9月至2014年4月,彿山市第一人民醫院採用Maastricht標準或中國標準,共穫取39例腦心死亡供肝.其中我院自行肝移植32例,5例供肝通過中國人體器官分配與共享繫統(COTRS繫統)分配到外院,2例棄用;對39例供體及彿山市第一人民醫院完成的33例肝移植(1例供肝通過COTRS繫統分配穫得)的臨床資料進行迴顧性分析總結.結果 33例供體中,中國Ⅰ類(C-Ⅰ),腦死亡供體(DBD)11例,中國Ⅲ類(C-Ⅲ),DBCD 22例.供者中位年齡38歲,腦死亡原因:車禍傷22例,腦齣血10例,腦榦腫瘤1例.DBCD供肝的熱缺血時間為3~21 min,平均為9.5 min;DBCD和DBD冷缺血時間為3.8~12.5 h,平均為5.2h.33例受者年齡38 ~64歲,中位年齡47.5歲.原髮病包括原髮性肝細胞癌11例,乙型肝炎後肝硬化8例,乙型肝炎急性肝功能衰竭6例,乙型肝炎慢加急性肝功能衰竭3例,丙型肝炎急性肝衰竭、乙肝閤併丙肝肝硬化、自身免疫性肝炎、酒精性肝硬化、多囊肝閤併多囊腎各1例.中位等待時間30 d,術後平均住院時間28.0 d,中位隨訪時間54週(13.5箇月).術後32例受者存活,無原髮性肝無功能髮生,1例術後第9天死于多器官功能衰竭.結論 腦心死亡供體肝移植是安全和可行的.供體的評估和有效維護,縮短熱、冷缺血時間,膽道併髮癥的防治,無激素免疫抑製方案以及覈苷類似物的應用等是保證供體肝移植成功實施的關鍵因素.
목적 탐토뇌심사망공체(DBCD)간이식적가행성화안전성.방법 2011년9월지2014년4월,불산시제일인민의원채용Maastricht표준혹중국표준,공획취39례뇌심사망공간.기중아원자행간이식32례,5례공간통과중국인체기관분배여공향계통(COTRS계통)분배도외원,2례기용;대39례공체급불산시제일인민의원완성적33례간이식(1례공간통과COTRS계통분배획득)적림상자료진행회고성분석총결.결과 33례공체중,중국Ⅰ류(C-Ⅰ),뇌사망공체(DBD)11례,중국Ⅲ류(C-Ⅲ),DBCD 22례.공자중위년령38세,뇌사망원인:차화상22례,뇌출혈10례,뇌간종류1례.DBCD공간적열결혈시간위3~21 min,평균위9.5 min;DBCD화DBD랭결혈시간위3.8~12.5 h,평균위5.2h.33례수자년령38 ~64세,중위년령47.5세.원발병포괄원발성간세포암11례,을형간염후간경화8례,을형간염급성간공능쇠갈6례,을형간염만가급성간공능쇠갈3례,병형간염급성간쇠갈、을간합병병간간경화、자신면역성간염、주정성간경화、다낭간합병다낭신각1례.중위등대시간30 d,술후평균주원시간28.0 d,중위수방시간54주(13.5개월).술후32례수자존활,무원발성간무공능발생,1례술후제9천사우다기관공능쇠갈.결론 뇌심사망공체간이식시안전화가행적.공체적평고화유효유호,축단열、랭결혈시간,담도병발증적방치,무격소면역억제방안이급핵감유사물적응용등시보증공체간이식성공실시적관건인소.
Objective To study the safety and feasibility of liver transplantation using brain and cardiac death donors.Methods The organs from 39 brain and cardiac death donors were harvested at the First People's Hospital of Foshan between September 2011 and April 2014.Five livers were allocated to other liver transplant centers through the China Organ Transplant Response System (COTRS).Two livers were discarded because of major injury and severe hepatic steatosis, respectively.The data of the 39 remaining donors and 33 liver transplant recipients with liver transplantation carried out in our department (including one liver accepted through the COTRS from another transplant center) were retrospectively analyzed.Results Among the 33 donors, 11 were in the China category Ⅰ and 22 category Ⅲ using the classification of China donor after cardiac death.The median age was 38 years.The primary causes of death were brain injury after road accident (n =22), cerebral hemorrhage (n =10), and brain tumor (n =1).The average warm ischemic time of the China category Ⅲ donors was 9.5 min (range 3 ~21 min).The average cold ischemic time of all the donors was 5.2 hours (ranged 3.8 ~ 12.5 h).The median age of the liver transplant recipients was 47.5 years (range 38 to 64 years).The primary disease of the liver transplant recipients was liver cirrhosis due to hepatitis B virus (HBV) infection (n =8), liver failure due to hepatitis C virus (HCV) infection (n =1), liver cirrhosis due to combined HBV and HCV infection (n =1), autoimmune hepatitis (n =1), alcoholic liver cirrhosis (n =1), acute liver function failure due to HBV infection (n =6), acute on chronic liver failure due to HBV infection (n =3), polycystic liver and kidney (n =1), and hepatocellular carcinoma (n =11).The median wait for liver transplantation was 30 days.The median hospitalization after liver transplantation was 28.0 days.At a median follow up of 54 weeks (or 13.5 months), 32 liver recipients were alive and well.One liver recipient died on the ninth day after operation because of multi-organ failure.There was no primary graft non-functioning.Conclusions Liver transplantation using brain and cardiac death donors was safe and feasible.Important measures for success include optimal management of donors, reduction of warm and cold ischemic time, prevention of biliary complications, use of immunosuppression with non steroidals and nucleoside/nucleotide analogs.